Scholarlink

Background <p>HER2-positive breast cancer is characterized by the absence of estrogen and progesterone receptors and the overexpression of the HER2 receptor. Existing targeted therapies, leads to side effects like cardiotoxicity, diarrhoea and suffer from poor penetration of the blood brain barrier. Zinc oxide nanoparticles have emerged as a promising drug delivery platform by improving biocompatibility, selective cytotoxicity via reactive oxygen species generation and facilitating effective penetration across biological barriers.</p> Objective <p>Our aim was to synthesize and characterize the Fulvestrant-zinc oxide nanoparticles, evaluate its efficacy <i>in-vitro</i> and ascertain its potential as a therapeutic agent for HER2-positive breast cancer.</p> Methods <p>Pharmacogenomics and gene enrichment process were applied to select target by following computational drug design strategy. Based on molecular docking, MMGBSA and molecular dynamics were undertaken to assess the stability. Subsequently, Fulvestrant-zinc oxide nanoparticles were synthesized and characterized using FT-IR, SEM and DSC techniques. <i>In-vitro</i> assessments involved MTT assays and AO/EtBr staining method.</p> Results <p>Computational results showed Fulvestrant superior HER2 binding, confirmed by molecular dynamics studies. <i>In vitro</i> studies revealed cytotoxicity and apoptosis.</p> Conclusion <p>This study highlights the Fulvestrant-zinc oxide nanoparticles as a promising therapeutic intervention for HER2-positive breast cancer. By undergoing computational approaches, Network analysis and pharmacogenomics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer

  • 期刊论文

  • 发表日期：

    2026年1月8日

查看全文
  • Melphiya D,
  • Krishnan Namboori P. K,
  • Jawahar N,
  • Raman Rajeshkumar,
  • Esakkimuthukumar M,
  • Pritam Kayal,
  • Akey Krishna Swaroop,
  • Jubie S

摘要

Background

HER2-positive breast cancer is characterized by the absence of estrogen and progesterone receptors and the overexpression of the HER2 receptor. Existing targeted therapies, leads to side effects like cardiotoxicity, diarrhoea and suffer from poor penetration of the blood brain barrier. Zinc oxide nanoparticles have emerged as a promising drug delivery platform by improving biocompatibility, selective cytotoxicity via reactive oxygen species generation and facilitating effective penetration across biological barriers.

Objective

Our aim was to synthesize and characterize the Fulvestrant-zinc oxide nanoparticles, evaluate its efficacy in-vitro and ascertain its potential as a therapeutic agent for HER2-positive breast cancer.

Methods

Pharmacogenomics and gene enrichment process were applied to select target by following computational drug design strategy. Based on molecular docking, MMGBSA and molecular dynamics were undertaken to assess the stability. Subsequently, Fulvestrant-zinc oxide nanoparticles were synthesized and characterized using FT-IR, SEM and DSC techniques. In-vitro assessments involved MTT assays and AO/EtBr staining method.

Results

Computational results showed Fulvestrant superior HER2 binding, confirmed by molecular dynamics studies. In vitro studies revealed cytotoxicity and apoptosis.

Conclusion

This study highlights the Fulvestrant-zinc oxide nanoparticles as a promising therapeutic intervention for HER2-positive breast cancer. By undergoing computational approaches, Network analysis and pharmacogenomics.